Serotonin and depression: a disconnect between the advertisements and the scientific literature.
Level 5 - mechanism / opinion, no new human data
Narrative review/commentary evaluating direct-to-consumer advertising claims against scientific literature.
PubMed 16268734 · doi:10.1371/journal.pmed.0020392
What was done
The authors reviewed consumer advertising claims for selective serotonin reuptake inhibitor (SSRI) antidepressants regarding brain serotonin mechanisms and compared them to the available scientific literature.
What was found
The abstract provides no quantitative data or specific study counts. The authors argue that there is little scientific evidence supporting direct-to-consumer advertising assertions that SSRIs treat depression by correcting a brain serotonin deficiency.
Why it matters
It highlights a divergence between marketing claims presented to the public and the empirical evidence regarding the biological mechanisms of depression and SSRIs.
Limits
The abstract contains no empirical data, sample size, search methodology, or quantitative evaluation criteria, representing a narrative commentary rather than a systematic review.
Cited by
- supports Serious neuroscientists do not agree with or support the serotonin deficiency model of depression.